143 related articles for article (PubMed ID: 9444936)
1. Resistance to topoisomerase II poisons: is the answer in the promoter?
Kaufmann SH
Leuk Res; 1997; 21(11-12):1033-6. PubMed ID: 9444936
[No Abstract] [Full Text] [Related]
2. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
Capranico G; Binaschi M
Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; D'Incalci M
Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
[No Abstract] [Full Text] [Related]
7. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
Cancer Chemother Biol Response Modif; 1997; 17():114-31. PubMed ID: 9551211
[No Abstract] [Full Text] [Related]
8. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
Wilstermann AM; Osheroff N
Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
[TBL] [Abstract][Full Text] [Related]
9. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss JL; Nitiss KC
Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
[No Abstract] [Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to topoisomerases poisons.
Prost S
Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase enzymes as drug targets.
Guichard SM; Danks MK
Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
[TBL] [Abstract][Full Text] [Related]
14. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
O'Reilly EK; Kreuzer KN
Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
[TBL] [Abstract][Full Text] [Related]
15. Iridoids as DNA topoisomerase I poisons.
Gálvez M; Martín-Cordero C; Ayuso MJ
J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
[TBL] [Abstract][Full Text] [Related]
16. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
18. Topoisomerase poisons: harnessing the dark side of enzyme mechanism.
Froelich-Ammon SJ; Osheroff N
J Biol Chem; 1995 Sep; 270(37):21429-32. PubMed ID: 7665550
[No Abstract] [Full Text] [Related]
19. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Jensen LH; Renodon-Cornière A; Nitiss KC; Hill BT; Nitiss JL; Jensen PB; Sehested M
Biochem Pharmacol; 2003 Aug; 66(4):623-31. PubMed ID: 12906927
[TBL] [Abstract][Full Text] [Related]
20. Bimolane: in vitro inhibitor of human topoisomerase II.
Frantz CE; Smith H; Eades DM; Grosovsky AJ; Eastmond DA
Cancer Lett; 1997 Dec; 120(2):135-40. PubMed ID: 9461029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
